Editorial
Fluorodeoxyglucose F 18 Positron Emission Tomography Scanning in Thoracic Disease
Abstract
Positron emission tomography (PET) is based on the observation that tumor cells exhibit high glucose utilization.1 Though not unique to malignant cells, this feature prompted the development of a radiolabeled tagged glucose tracer that can assess tissue metabolism. Fluorodeoxyglucose F 18 (FDG) is the tracer most widely used in clinical practice. Positrons emitted from the tracer release two high-energy photons when they collide with electrons. Detectors record the dual photon emission, and computer software accurately maps their origin. Data can be displayed in individual planes or as a three-dimensional image. Scans are interpreted visually or quantitatively, using what is known as the standardized uptake value (SUV). A value greater than 2.5 is usually considered to indicate malignancy.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.